Cancer Vaccine, China Deals, Biopharma Shifts
Kilder
- STAT: STAT+: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
- Bostonglobe: Moderna stock plummets even after data confirm cancer vaccine with Merck met key endpoints in melanoma trial - The Boston Globe
- Thehill: MAHA leader resigns from administration - The Hill
- STAT: STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
- Fierce Biotech: Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals - Fierce Biotech
- Reuters: US Treasury drops Venezuela from countries facing outbound US investment restrictions - Reuters
- Politico: Biotech investment is the new front in the U.S.-China trade fight - Politico
- Endpoints: Gilead strikes $1.3B upfront China deal for oral IL-23 drug
- Endpoints: A hepatitis B hold lifted and drug tabled; Ultomiris' accelerated approval
- Endpoints: Georgiamune sells solid tumor drug to Italy's Menarini for up to $1.1B
- Raps: Recon: FDA approves GSK hepatitis B drug; EQT to buy molecular testing firm Qiagen for $10.8B - RAPS
- Macaubusiness: Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent - Macau Business
- wikimedia: Photo by G. Edward Johnson / Wikimedia Commons / CC BY 4.0
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.